2-DG Inhibits SARS-COV-2 Growth and Cyto-Pathic Effect

2-DG Inhibits SARS-COV-2 Growth and Cyto-Pathic Effect:



2-DG released

  • The first batch of the indigenously developed anti-Covid drug, 2-Deoxy-D-Glucose oral powder or ‘2-DG’ released by Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan on Monday (May 17).
  • Developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), New Delhi, a lab of the Defence Research and Development Organisation (DRDO), in association with Hyderabad-based Dr Reddy’s Laboratories (DRL)
  • Drugs Controller General of India (DCGI) cleared the formulation on May 1 for emergency use to be used together with the primary treatment in both moderate and severe Covid-19 patients

To buy our online courses:  Click Here


  • Clinical trials show that the molecule helps in faster recovery of patients hospitalised with Covid-19 and reduces their dependence on auxiliary oxygen
  • Patients improved symptomatically and become free from supplemental oxygen dependence by 42% on the 3rd day when compared to 31% using traditional SoC.
  • A 2.5 days difference in median time to achieve normalisation of specific vital sign parameters when compared to SoC.


  • Phase 2 trials conducted on 110 patients between May and October 2020
  • Phase 2A was conducted in six hospitals,
  • Phase 2B involved dose-ranging (clinical trial using different doses) was conducted in 11 hospitals across the country
  • Phase 3 clinical trials in November 2020
  • Final trials were carried out on 220 patients admitted to 27 Covid hospitals in various districts between December 2020 and March 2021

How it works

  • 2-DG drug spreads through the body just like glucose. The virus needs glucose for energy. Replica of glucose/ glucose analogue forces the virus to think it is glucose.
  • It reaches the virus-infected cells and prevents virus growth by stopping viral synthesis. Glycolysis, the breakdown of glucose to extract energy for cellular metabolism stops and so does energy production.
  • It gets inside the virus-cell and cuts off the glucose required for the virus to grow. The virus stops multiplying automatically. Helps in reducing the infection and the viral load gradually
  • Its selective accumulation in virally infected cells makes this drug unique


  • 10000 doses expected to be released for trial
  • The anti-COVID drug 2-DG has been developed in powder form and is ingested orally by dissolving it in water
  • A patient may have to take this drug twice a day for about five to seven days.

Availability and price

  • 2-DG being a generic molecule and an analogue of glucose, it can be easily produced and made available in large quantities
  • Supply to major hospitals to begin by mid-June
  • It will be low-cost and will be priced inexpensively

(2-DG Inhibits SARS-COV-2 Growth and Cyto-Pathic Effect)

Also Read: New Shrew like mammal discovered